Abstract
POSTER: AML-530 Sequential Salvage Chemotherapy and Lintuzumab-Ac225 in Relapsed/Refractory AML Results in Deep Responses and Prolonged Survival in Adverse Risk Acute Myeloid Leukemia (AML) and in AML Patients that Received Prior Venetoclax Therapy
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have